Significant Agreements - Additional Information (Detail) - USD ($) $ in Thousands	1 Months Ended		3 Months Ended			6 Months Ended		12 Months Ended
	Oct. 31, 2017	Jul. 31, 2016	Jun. 30, 2025	Jun. 30, 2024	Jun. 30, 2022	Jun. 30, 2025	Jun. 30, 2024	Dec. 31, 2016
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Research and development expense			$ 62,227	$ 48,655		$ 123,863	$ 105,147
Allergan License Agreement Member \| Vitae Pharmaceuticals Inc [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Potential milestone payments to be made	$ 99,000		68,000			68,000
Aggregate potential milestone payable	$ 70,000
License expiration year	10 years
Milestone Expenses Paid			5,000			5,000
Development and regulaotry milestones Expenses			31,000			31,000
UCB License Agreement [Member] \| UCB Biopharma [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Potential milestone payments to be made		$ 119,500	78,500			78,500
Aggregate potential milestone payable		$ 250,000
License expiration year		10 years
Research and development expense								$ 5,000
Milestone payment payable					$ 5,800
Development and regulaotry milestones Expenses			$ 41,000			$ 41,000